Τίτλος:
Non-platinum-based first-line followed by platinum-based second-line chemotherapy or the reverse sequence in patients with advanced non-small cell lung cancer: A retrospective analysis by the lung cancer group of the hellenic oncology research group
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background: Non-platinum-containing regimens have been proposed as alternatives to platinum-based doublets in the first-line treatment of patients with non-small cell lung cancer (NSCLC). However, conflicting results about their equivalence have been reported. Methods: We reviewed the records of patients enrolled in randomized controlled first-line trials conducted by the Hellenic Oncology Research Group from February 1997 to September 2006. The outcome of patients treated with first-line non-platinum-based chemotherapy who received platinum-based chemotherapy upon progression (cohort A) or platinum-based first-line chemotherapy followed by non-platinum-containing second-line chemotherapy (cohort B) was retrospectively analyzed. Results: Two-hundred and sixty-seven patients were identified in cohort A, and 123 in cohort B. Median follow-up time was 12.5 and 15.7 months for cohorts A and B. A significantly higher response rate and time to tumor progression (TTP) was recorded for patients treated with platinum-based compared to those receiving non-platinum-based first-line chemotherapy (45.5 vs. 21.3%, p < 0.0001 and 5.8 vs. 3.1 months, p= 0.002, respectively). Platinum-based regimens administered as second-line treatment resulted in a 13.1% response rate. TTP for second-line chemotherapy did not differ significantly between the two cohorts. Median overall survival was 13.3 and 15.7 months for cohorts A and B (p = 0.538). Conclusion: Both sequences resulted in similar efficacy in terms of overall survival. Encouraging median survival was achieved for selected patients with NSCLC who received both first-and second-line chemotherapy. © 2010 S. Karger AG, Basel.
Συγγραφείς:
Agelaki, S.
Hatzidaki, D.
Kotsakis, A.
Papakotoulas, P.
Polyzos, A.
Ziras, N.
Gioulbasanis, I.
Karampeazis, A.
Agelidou, A.
Tsiafaki, X.
Chandrinos, V.
Lerikou, M.
Georgoulias, V.
Περιοδικό:
DIAGNOSTIC ONCOLOGY
Λέξεις-κλειδιά:
cisplatin; docetaxel; etoposide; gemcitabine; ifosfamide; irinotecan; mitomycin; navelbine; oxaliplatin; pemetrexed; platinum derivative; taxane derivative; topotecan, adult; advanced cancer; aged; article; cancer combination chemotherapy; clinical trial; controlled clinical trial; controlled study; female; follow up; human; lung non small cell cancer; major clinical study; male; priority journal; randomized controlled trial; retrospective study; treatment outcome; treatment response, Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; Female; Greece; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Treatment Outcome
